Community-acquired pneumonia in adults

Size: px
Start display at page:

Download "Community-acquired pneumonia in adults"

Transcription

1 Prim Care Clin Office Pract 30 (2003) Community-acquired pneumonia in adults Julio A. Ramirez, MD a,b, * a Department of Medicine, University of Louisville School of Medicine, 512 S. Hancock Street, Carmichael Building, Room 208-D, Louisville, KY 40202, USA b Department of Veterans Affairs Medicine Center, 800 Zorn Avenue, Louisville, KY 40206, USA Community-acquired pneumonia (CAP) is a serious respiratory tract infection that is routinely managed by primary care physicians. In the United States, pneumonia is the sixth leading cause of death and the number-one cause of death from infectious diseases. It is estimated that up to 5.6 million cases of CAP occur annually, and as many as 1.1 million of these cases require hospitalization. The incidence of CAP is weighted heavily toward the winter months [1,2]. The mortality rate of pneumonia remains low in the outpatient setting, with a mortality range of less than 1% to 5%, but among patients with CAP who require hospitalization, the mortality rate averages 12% overall. For the hospitalized patient with serious CAP requiring admission in the intensive care unit, the mortality may reach 40% [1,2]. Pathogenesis and clinical presentation Pneumonia indicates an inflammatory process of the lung parenchyma that is caused by a microbial agent. The most common pathway for the microbial agent to reach the alveoli is by microaspiration of oropharyngeal secretions. Once microorganisms reach the alveolar space, to cause pneumonia, they must overcome the last defense mechanism of the lung, the alveolar macrophage. Most of the time the alveolar macrophage will phagocytize and kill the microorganisms that reach the alveolar space, which explains why the presence of clinical pneumonia is infrequent, even though the arrival of microorganisms to the alveolar space is not an infrequent occurrence. * Department of Veterans Affairs Medicine Center, 800 Zorn Avenue, Louisville, KY 40206, USA. address: j.ramirez@louisville.edu /03/$ - see front matter Ó 2003, Elsevier Science (USA). All rights reserved. doi: /s (02)

2 156 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) If the alveolar macrophage is unable to control the growth of the microorganisms, then as a final protective defense mechanism, the lungs develop a local inflammatory response. This local inflammatory response is characterized by movement of white blood cells, lymphocytes, and monocytes from the capillaries into the alveolar space. The recruitment of phagocytic cells to the alveolar space is mediated primarily by tumor necrosis factor and interleukin-1 produced by the alveolar macrophages. In addition to tumor necrosis factor and interleukin-1, other important locally produced cytokines include interleukin-6, interleukin-10, interleukin-12, monocyte chemotactic factor 1, and granulocyte colony-stimulating factor [3]. Once these cytokines reach the systemic circulation, they also produce a systemic inflammatory response. The local and systemic inflammatory response is responsible for most of the signs, symptoms, and laboratory abnormalities that characterize the CAP syndrome. The patient with pneumonia syndrome presents with cough, sputum production, shortness of breath, pleuritic chest pain, fever, chills, tachycardia, tachypnea, rales, and signs of consolidation on physical examination, and leukocytosis, left shift, and a new pulmonary infiltrate on chest radiograph. Several of these abnormalities are due to the local inflammatory response produced by the arrival of white blood cells into the alveolar space. The development of cough and sputum production are caused by the excess of white blood cells in the alveoli. The shortness of breath and hypoxemia are secondary to the accumulation of cells in the alveolar space producing a ventilation-perfusion mismatching. The presence of a new pulmonary infiltrate on the chest radiograph is predominately attributable to the buildup of inflammatory cells in the alveoli. Other manifestations of the pneumonia syndrome are due to the systemic inflammatory response. The presence of fever is mediated primarily by the action of interleukin-1 and other mediators that act over the thermoregulatory center at the level of the hypothalamus. The presence of leukocytosis and left shift is mediated primarily by the action of granulocyte colonystimulating factors over the bone marrow. Because the clinical and laboratory presentation of patients with CAP is caused mostly by the host inflammatory response, the clinical presentation itself is not characteristic of any particular etiologic agent. It is no longer recommended to consider a patient as having a typical or atypical etiology of CAP based on the patient s clinical presentation. Clinical diagnosis Because of their low sensitivity and specificity, history and physical examination are considered suboptimal to confirm or exclude the diagnosis of CAP [4]. National guidelines recommend that a new pulmonary infiltrate on a chest radiograph should be present to classify a hospitalized patient as

3 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) having the diagnosis of CAP [1,2]. The clinical diagnosis requires evidence of a new pulmonary infiltrate compatible with pneumonia associated with other signs and symptoms characteristic of the pneumonia syndrome. Because the clinical diagnosis of CAP is based on a clinical syndrome, it is expected that in some hospitalized patients with a clinical diagnosis of CAP, an alternative diagnosis will explain the signs and symptoms of the patient. Sometimes the patient may have cough, sputum production, and fever; however, the infection may not represent pneumonia but rather acute exacerbation of chronic bronchitis or acute bronchitis. In this type of patient, there is no evidence of a new pulmonary infiltrate. In patients with a pulmonary infiltrate at admission to the hospital, the pulmonary infiltrate may not represent a new infiltrate but a chronic infiltrate representing old pulmonary changes. In some patients with a new pulmonary infiltrate, the infiltrate may be attributable to an alternative diagnosis, such as pulmonary embolism. In a study performed in the author s institution, it was found that the most common clinical scenario that is associated with a misdiagnosis of CAP is the patient admitted to the hospital with cough and a new pulmonary infiltrate that are due to an exacerbation of congestive heart failure [5]. Need for hospitalization During the initial evaluation of the patient with CAP, physicians need to define the patient s severity of disease and the intensity of care that will be necessary for the patient to achieve an optimal outcome. If the level of care that the patient can receive at home is not sufficient, the patient requires hospitalization. Hospitalization permits the use of intravenous antibiotics, intravenous fluids, hemodynamic support, supplemental oxygen, mechanical ventilation, and aggressive therapy for comorbidity and facilitates several clinical evaluations during the day performed by nurses and physicians. Hospitalization based on patient s risk for mortality A two-step prediction rule to identify low-risk patients with CAP was derived using data from 14,199 adults with CAP [6]. To parallel physician decision-making processes, the prediction rule was developed in two steps. Step 1 This step identified a subgroup of patients at low risk for death solely on the basis of their history and physical examination findings. These patients are classified as class I (Table 1). Step 2 The risk of death was quantified in the remaining patients with the same 11 findings used in step 1 plus two demographic factors and seven laboratory or radiographic findings. A scoring system was used to measure the

4 158 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Table 1 Step 1 of the pneumonia severity index 1. Age >50 years? 2. Coexisting conditions? 2.1 Neoplastic disease 2.2 Congestive heart failure 2.3 Cerebrovascular disease 2.4 Renal disease 2.5 Liver disease 3. Abnormalities at PE? 3.1 Altered mental status 3.2 HR >125/min 3.3 RR >30/min 3.4 Systolic BP <90 mm Hg 3.5 Temperature <35 Cor>40 C If none of these 11 risk factors is present, the patient is assigned to risk class I. Abbreviations: BP, blood pressure; HR, heart rate; PE, physical examination; RR, respiratory rate. magnitude of association of these factors with mortality and to assign patients a total number of points (Table 2). Based on the total points assigned, patients are classified in risk class II (70 points), risk class III (71 90 points), risk class IV ( points), or risk class V (>130 points). Among the different classes, the mortality rate is 0.1% for class I patients, 0.6% for class II patients, 2.8% for class III patients, 8.2% for class IV patients, and 29.2% for class V patients. Patients 50 years of age or younger who have none of the coexisting illnesses or physical findings identified as class I are considered candidates for outpatient treatment. Importantly, physicians can make this determination on the basis of information obtained from the initial history and physical examination without having to order laboratory tests, which may be costly and time consuming. Patients assigned to risk class II are considered candidates for outpatient therapy. Patients assigned to risk classes III, IV, or V are considered candidates for hospitalization. Hospital-admission decision Even with the availability of risk-stratification data, the admission decision is ultimately an art-of-medicine decision that should be individualized carefully. Nonclinical factors such as patient preference and social considerations also may influence the site-of-care decision. It is important to keep in mind that the decision to hospitalize is not necessarily a commitment to long-term inpatient care. Rather, it is a decision that certain patients should be observed closely until it is evident that their infection is responding to therapy.

5 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Table 2 Step 2 of the pneumonia severity index: point score according to patient s characteristics 1. Demographic factor Age (y) Men Age Women Age ÿ Nursing home resident þ10 3. Coexisting conditions Neoplastic disease þ30 Liver disease þ20 Congestive heart failure þ10 Cerebrovascular disease þ10 Renal disease þ10 4. Physical examination findings Altered mental status þ20 Respiratory rate >30 þ20 Systolic BP <90 þ20 Temperature <35 Cor>40 C þ15 Pulse >125 þ10 5. Laboratory and radiographic findings Arterial ph <7.35 þ30 BUN >30 mg/dl þ20 Sodium <130 mmol/l þ20 Glucose >250 mg/dl þ10 Hematocrit <30% þ10 PaO 2 <60 mm Hg þ10 Pleural effusion þ10 Abbreviation: BUN, blood urea nitrogen. Etiology of community-acquired pneumonia In clinical studies designed to identify the etiology of CAP using reference microbiology laboratories, a specific pathogen is not identified in approximately 50% of the patients [1,2]. In everyday practice, clinicians are expected to encounter pneumonia of unknown etiology in more than half of the hospitalized patients with CAP. The etiology of CAP can be classified into the following four groups: (1) CAP caused by typical or conventional bacteria, (2) CAP caused by atypical bacteria, (3) CAP caused by other agents, and (4) CAP of unknown etiology. The incidence of the most common organisms causing CAP, according to a review of the literature performed by the author, is depicted in Table 3. In an attempt to define if a typical pathogen is the etiology of pneumonia, it is recommended that all patients should have a sputum specimen for gram stain and culture and two sets of blood cultures obtained before the institution of antimicrobial therapy [1,2]. The quality of sputum specimen should be determined by gram stain results. Only sputum specimens that contain a large number of leukocytes and a minimal number of epithelial cells per low-power field should be accepted for bacterial culture. The urinary

6 160 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Table 3 Etiology of community-acquired pneumonia based on a review of published articles 1. Typical pathogens 40% 60% Streptococcus pneumoniae 15% 25% Haemophilus influenzae 2% 10% Moraxella catharralis 0% 5% 2. Atypical pathogens 10% 30% Mycoplasma pneumoniae 1% 10% Chlamydia pneumoniae 5% 15% Legionella pneumophila 0% 15% 3. Other pathogens 5% 25% Viral agents 2% 15% Pneumocystis carinii 0% 10% Mycobacterium tuberculosis 0% 10% 4. Unknown etiology 30% 60% antigen test for detection of Legionella pneumophila is recommended in patients with severe CAP who are hospitalized in the intensive care unit [2]. Antimicrobial therapy The primary antibiotic families used to treat CAP are the beta-lactams, macrolides, quinolones, and tetracyclines. In an attempt to help the practicing physician with antibiotic selection, national organizations in the United States and Canada have published guidelines for therapy for patients with CAP [1,2,7,8]. All documents support certain basic principles of antibiotic therapy for patients with CAP. These principles can be summarized as follows: (1) resistant pathogens tend to infect patients with certain clinical risk factors, (2) identification of these risk factors for infection with resistant pathogens allows the classification of patients into different groups, (3) the initial empiric therapy should be tailored to cover only the likely pathogens for a particular group of patients with CAP, (4) initial empiric therapy with a spectrum of activity that is broader than necessary is not appropriate because this practice favors development of pathogen resistance without improving patient outcome, and (5) in hospitalized patients, it is safe to switch from intravenous to oral therapy once there is documented clinical improvement. The list of organisms able to cause CAP is extensive. Using broadspectrum empiric antibiotics to cover all pathogens in all patients is inappropriate, because not all patients are at risk of infection for all possible etiologic agents. In an attempt to limit the list of likely organisms for a particular patient, all guidelines for therapy classify patients into different groups. For each particular group, there is a limited number of organisms likely to cause CAP. Classification of patients into groups allows for a more rational approach to initial empiric therapy. Patients are classified according to the severity of disease, the site of care, and the presence or absence of risk factors for a particular resistant organism.

7 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Severity of disease and site of care Patients with CAP can be classified initially according to the severity of disease and site of care. Patients with mild disease will be treated as outpatients, patients with moderate disease will be hospitalized and treated in a medical ward, and patients with severe disease requiring cardioventilatory support will be hospitalized and treated in an intensive care unit. Risk factors for resistant organisms The fact that penicillin-resistant Streptococcus pneumoniae (PRSP) is present in a particular region is not an indication that all patients in that region are at similar risk for developing CAP due to PRSP. Based on published studies, one can identify risk factors for PRSP and risk factors for other resistant organisms. Considering the presence or absence of risk factors, one can define the list of likely invading organisms for a particular patient with CAP. Patient with no risk factors A young patient without any risk factors for resistant pathogens is likely to be infected with one of the core organisms: penicillin-susceptible Streptococcus pneumoniae, Mycoplasma pneumoniae, orchlamydia pneumoniae. These three pathogens are considered as a group of core pathogens that can be the etiology of CAP in any patient. Risk factors for penicillin-resistant Streptococcus pneumoniae The risk factors for PRSP include age older than 65 years, being a nursing home resident, alcoholism, recent use of beta-lactam antibiotics, immunosuppression, multiple medical comorbidities, recent hospitalization, or exposure to a child in a day care center. Risk factors for macrolide-resistant Streptococcus pneumoniae Although S. pneumoniae has different mechanisms of resistance for penicillin than macrolides, the strains of S. pneumoniae that are resistant to penicillin are likely to be erythromycin-resistant. Because there is no difference among the macrolides in regard to S. pneumoniae susceptibility, identification of erythromycin resistance is equivalent to resistance for all the macrolide family. Patients with risk factors for infection due to PRSP should be considered to be at risk for infection with macrolide-resistant S. pneumoniae. Risk factors for Haemophilus influenzae and Moraxella catarrhalis The risk factors include a history of smoking or chronic obstructive pulmonary disease (COPD).

8 162 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Risk factors for gram-negative Enterobacteriaceae Risk factors for gram-negative Enterobacteriaceae include those who are elderly patients or nursing home residents or those with a history of alcoholism, immunosuppression, recent antibiotic therapy, multiple medical comorbidities, or recent hospitalization. Risk factors for Pseudomonas aeruginosa Patients with COPD complicated with bronchiectasis, chronic broadspectrum antibiotic use, corticosteroid therapy, malnutrition, or neutropenia are at risk for Pseudomonas aeruginosa. Risk factors for anaerobes Patients with a history of alcoholism, poor dental hygiene, suspected large-volume aspiration, or airway obstruction are at risk for anaerobes. Classification of patients Considering the severity of disease, site of care, and the presence or absence of risk factors for a particular resistant organism, patients are classified into groups. A considerable agreement among guidelines can be obtained if patients are classified into five groups (Fig. 1). Ambulatory patients are classified into groups 1 and 2. Patients treated in the medical Fig. 1. Classification of patients based on severity of pneumonia, site of care, and risk factors for resistant organisms.

9 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) ward are classified as group 3. Patients admitted to the intensive care unit are classified into groups 4 and 5. The list of likely organisms able to cause pneumonia increases as the severity of disease increases and the patient moves from group 1 classification with mild CAP requiring outpatient therapy to group 5 classification with severe CAP requiring therapy in the intensive care unit. This increase in likely pathogens with increased severity of disease is due to the likelihood of a greater number of risk factors in patients with more severe CAP. Empiric therapy for the ambulatory patient: groups 1 and 2 According to the presence of risk factors for particular resistant organisms, the ambulatory patients with CAP can be classified into groups 1 and 2 (Fig. 2). These groups define the likely pathogens and optimal empiric oral therapy. Some patients may have risk factors for more than one resistant pathogen. The basic core organisms described in group 1 should be covered by any selected empiric therapy. Group 1 This group includes patients with no risk factors for resistant organisms or patients with smoking and COPD as the only risk factors. Likely organisms in these patients include the core pathogens penicillin-susceptible Streptococcus pneumoniae, Mycoplasma pneumoniae, andchlamydia pneumoniae, with the addition of H. influenzae or M. catarrhalis in smokers with Fig. 2. Likely organisms and empiric antibiotic therapy for patients in groups 1 and 2 (see text for specific antibiotics and details).

10 164 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) COPD. These patients can be treated with a new-generation macrolide such as clarithromycin or azithromycin. Doxycycline can be selected in regions where S. pneumoniae remains susceptible to tetracyclines. A patient in group 1, without a history of smoking or COPD, can be treated empirically with erythromycin. Because erythromycin has poor activity against H. influenzae, it is not recommended for smokers or patients with COPD. Group 2 This group includes patients with risk factors for PRSP or Enterobacteriaceae. These patients can be treated with monotherapy using a new-generation quinolone (eg, levofloxacin, gatifloxacin, or moxifloxacin). Another appropriate regimen is combination therapy using a beta-lactam (eg, amoxicillin, amoxicillin-clavulanate, cefuroxime, or cefpodoxime) to cover for resistant pathogens, plus a macrolide (eg, erythromycin, clarithromycin, or azithromycin) or tetracycline (eg, doxycycline) to cover for atypical pathogens. Empiric therapy for the patient in the hospital ward: group 3 In an attempt to decrease cost of care, there is a trend to treat patients with mild CAP in the outpatient setting with oral antibiotics. As a consequence, the population of hospitalized patients tends to be elderly with multiple medical comorbidities, with an increasing number of patients who have already failed to respond to outpatient oral antibiotic therapy. It is considered that most hospitalized patients in a medical ward have some of the risk factors for resistant S. pneumoniae or Enterobacteriaceae and can be classified into a single group (Fig. 3). Group 3 This group includes those at risk for PRSP or Enterobacteriaceae. These patients can be treated with monotherapy using an intravenous new-generation quinolone (eg, levofloxacin, gatifloxacin, or moxifloxacin) or with intravenous combination therapy with a beta-lactam, such as a second- or third-generation intravenous cephalosporin (eg, cefuroxime, cefotaxime, ceftriaxone) or beta-lactam, with beta-lactamase inhibitor (eg, ampicillin-sulbactam), plus an intravenous macrolide to cover atypical pathogens. Data are not available to define which initial empiric regimen (quinolone versus beta-lactam plus macrolide) is the one associated with better patient outcome or decreased cost of therapy. If a hospitalized patient has additional risk factors for anaerobes, the anti-anaerobic activity of the initial intravenous empiric therapy should be considered. In this situation, the preferred intravenous quinolone is moxifloxacin and the preferred betalactam is a combination of beta-lactam with a beta-lactamase inhibitor.

11 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Fig. 3. Likely organisms and empiric antibiotic therapy for patients in group 3 (see text for specific antibiotics and details). Empiric therapy for the patient in the intensive care unit: groups 4 and 5 All patients with severe CAP who require admission to the intensive care unit should be considered at risk for infection with a series of resistant organisms. Patients hospitalized in the intensive care unit can be classified into groups 4 and 5 (Fig. 4). Group 4 This group includes patients likely to be infected with one or more of the following antibiotic resistant organisms: PRSP, Haemophilus influenzae, Moraxella catarrhalis, Enterobacteriaceae, and Legionella spp. These patients can be treated with a combination of a third-generation intravenous cephalosporin (cefotaxime or ceftriaxone) plus an intravenous macrolide (erythromycin or azithromycin), or they can be treated with a combination of a third-generation intravenous cephalosporin (cefotaxime or ceftriaxone) plus an intravenous new-generation quinolone (levofloxacin, gatifloxacin, or moxifloxacin). Group 5 This group includes patients at risk for infection with the resistant pathogens described in group 4 plus risk factors for infection with Pseudomonas aeruginosa. The goal in selecting empiric therapy for this

12 166 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Fig. 4. Likely organisms and empiric antibiotic therapy for patients in groups 4 and 5 (see text for specific antibiotics and details). group of patients is to cover the pathogens described in group 4 and to generate a regimen with synergistic activity against Pseudomonas aeruginosa. These patients can be treated with a combination of an intravenous beta-lactam antibiotic with good activity against PRSP and Pseudomonas aeruginosa (eg, imipenem, meropenem, piperacillin/tazobactam, cefepime) plus an intravenous quinolone with good activity against Legionella spp and Pseudomonas aeruginosa (eg, ciprofloxacin). Another option for this group of patients is to achieve combination therapy against P. aeruginosa with a combination of a beta-lactam plus an aminoglycoside, adding a quinolone or a macrolide to cover for Legionella. Timely administration of antibiotics For hospitalized patients with CAP, guideline documents indicate that it is important to give the first dose of antibiotic as soon as possible after hospital arrival. Delayed antibiotic administration in hospitalized patients with CAP is associated with lower outcomes. This concept is based primarily on a large retrospective study performed in the United States that indicated that in patients 65 years or older, those receiving antibiotics within 8 hours of their hospital arrival had a 20% to 30% decrease in 30 days mortality compared with those who received antibiotics after 8 hours of hospital arrival [9]. Although there are no studies to evaluate timing of antibiotic administration in younger patients, it is now recommended that

13 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) all hospitalized patients with CAP should receive the first dose of antibiotic within 8 hours of hospital arrival. Switching from intravenous to oral therapy Expected clinical course If empiric therapy is initiated according to guidelines, most hospitalized patients with CAP show evidence of clinical improvement. The expected course of a hospitalized patient with clinical improvement can be divided into three different periods [10]: a first period when the patient is clinically unstable, a second period of early clinical improvement, and a third period of definitive clinical improvement. The first period starts with the initiation of parenteral antimicrobial therapy. Despite appropriate empiric antimicrobial therapy, most patients remain clinically unstable for 48 to 72 hours. Because of this finding, it is not recommended to change the initial antimicrobial regimen during the first 48 to 72 hours unless there is a marked clinical deterioration. The second period starts when the patient reaches the point of clinical stability. During this second period, the signs, symptoms, and laboratory abnormalities caused by the infection begin to normalize, and the patient shows evidence of initial clinical improvement. During the third period of recovery, the signs, symptoms, and laboratory abnormalities are greatly improved or resolved. When to consider switch therapy The decision regarding when to switch from intravenous to oral antibiotics should be based on the patient s clinical response to therapy. Close evaluation of signs and symptoms such as cough, sputum production, shortness of breath, fever, and leukocytosis identifies the patient who reaches clinical stability. Recent clinical trials have indicated that in hospitalized patients with CAP, the switch to oral therapy can be performed safely once the patient reaches the point of clinical stability and enters the second period of recovery (Fig. 5). A patient can be considered to reach clinical stability and be a candidate for switch therapy when the following four criteria are met: (1) cough and shortness of air are improving, (2) the patient is afebrile (temperature <100 F) for at least 8 hours, (3) the white blood cell count is normalizing, and (4) oral intake and gastrointestinal absorption are adequate [1]. Based on these criteria, most patients reach clinical stability and are candidates for oral therapy during the first 3 days of treatment [11]. Because improvement in the chest radiograph lags behind clinical improvement, it is not recommended to repeat a chest radiograph to evaluate if the patient has reached clinical stability. It is not unusual to have a patient who is clinically improving at the time that the chest radiograph is unchanged or even deteriorating.

14 168 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Fig. 5. Time to switch therapy during the recovery phase of patients with CAP. Selection of oral antibiotics Before initiation of initial intravenous empiric therapy, appropriate culture specimens of respiratory secretions and blood are obtained. If the cultures identify the etiology of CAP, the spectrum of initial empiric therapy can be narrowed to cover only the identified pathogen. This change from a broad-spectrum intravenous therapy to a more narrow-spectrum intravenous therapy is defined as known-pathogen therapy or pathogen-directed therapy. In a patient who is clinically improving, the switch from intravenous to oral therapy can be performed from known-pathogen therapy or from empiric therapy (Fig. 6). When the pathogen causing CAP is known, the choice of the oral antimicrobial for switch therapy is based on the susceptibility pattern of the identified microorganism. In patients with CAP, it is unusual to identify a definitive pathogen. As such, the most common scenario is a switch to oral antibiotics from empiric parenteral therapy. In this clinical situation, the oral antibiotic should be equivalent to the intravenous empiric regimen regarding spectrum of antimicrobial activity. Because intravenous antibiotics are discontinued during the early phase of recovery, the patient s compliance with the oral antibiotic regimen is of paramount importance. Patients should be given explicit instructions regarding the potential for drug-drug or drug-food interactions (eg, quinolones-antacids) to avoid reduced absorption of oral antibiotics. Correlation of switch therapy with early hospital discharge Clinical improvement during the initial 3 days of intravenous treatment is seen in a number of hospitalized patients with CAP. The ideal model to

15 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) Fig. 6. Selection of oral antibiotics for switch therapy. decrease treatment cost for the full population of hospitalized patients with CAP is to perform early switch to oral therapy followed by early hospital discharge in a significant number of patients. At least three factors may be present in a population of patients with CAP that will impede this ideal model of early switch to oral therapy followed by early hospital discharge. First, a subgroup of hospitalized patients will deteriorate clinically on empiric intravenous therapy and will not be candidates for oral antibiotics. Second, among the population that responds to intravenous antibiotics, a subgroup of patients will have a late clinical response and will not be candidates for early use of oral antibiotics. Third, even if all patients who show evidence of early clinical improvement during the first 3 days of treatment are switched to oral therapy, hospital discharge may be delayed in some of these patients because of conditions not related to pneumonia. If none of these three factors is present, the patient can be managed with the ideal model of early switch early discharge. In a recent study, it was documented that 65% of hospitalized patients with CAP can be switched to oral therapy during the first 3 days of hospital therapy [11]. It should be expected that almost half of the population of hospitalized patients with CAP can be managed safely with the approach of early switch followed by early discharge. Prevention of community-acquired pneumonia During epidemics of influenza, there is an increase in the frequency of CAP due to primary influenza pneumonia and secondary bacterial

16 170 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) pneumonia complicating a case of influenza. Influenza vaccine is effective in limiting the severity of disease caused by the influenza virus. The pneumococcal vaccine has been proven to prevent pneumococcal pneumonia in young adults. The efficacy of the vaccine tends to decline with age and in patients who are immunocompromised. The population of hospitalized patients with CAP should be considered a high-risk population for rehospitalization related to influenza or pneumonia. Hospitalized patients with CAP should be evaluated to define if they are candidates for vaccination, and candidates should be vaccinated before hospital discharge [1,2]. There is no contraindication for the use of the pneumococcal vaccine and the influenza vaccine after an episode of CAP. These vaccines can be given simultaneously at different sites, without increasing side effects [12]. When patients are hospitalized during the influenza season, they can be considered at risk for acquiring influenza from an infected health care worker. The vaccination of health care workers can be seen as an important strategy for the prevention of influenza in vulnerable hospitalized patients. Because smoking is a definitive risk factor for the acquisition of pneumonia, all hospitalized patients with CAP should be advised to be enrolled in a smoking-cessation program in an attempt to prevent relapse of pneumonia. Summary The most common etiologic agent of CAP is Streptococcus pneumoniae. Atypical pathogens are the cause in approximately 20% to 30% of patients. Because the patient s clinical presentation cannot be used to predict if a patient is infected with S. pneumoniae or an atypical pathogen, the initial empiric therapy should cover for these core organisms in all patients. In patients with CAP, the antibiotic spectrum of initial empiric therapy will escalate from an oral macrolide in an ambulatory patient without risk factors for resistant pathogens, to intravenous combination therapy, in a hospitalized patient in the intensive care unit with risk factors for resistant gram-negative organisms. The hospitalized patient can be switched safely from intravenous to oral therapy once he or she reaches clinical stability. The use of pneumococcal vaccine, influenza vaccine, and smoking-cessation programs is an important strategy to prevent CAP. References [1] Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. American Thoracic Society. Am J Respir Crit Care Med 2001;163: [2] Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2000;31:

17 J.A. Ramirez / Prim Care Clin Office Pract 30 (2003) [3] Nelson S, Mason CM, Kolls J, Summer WR. Pathophysiology of pneumonia. Clin Chest Med 1995;16:1 12. [4] Wipf JE, Lipsky BA, Hirschmann JV, et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999;159: [5] Ahkee S, Barzallo M, Ramirez J. Empiric antibiotic therapy in patients without documented infections. Infections in Medicine 1996;13:800 2, 823. [6] Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336: [7] Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160: [8] Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31: [9] Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278: [10] Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995;2: [11] Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159: [12] Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunization with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ 1997;314:

Community-Acquired Pneumonia OBSOLETE 2

Community-Acquired Pneumonia OBSOLETE 2 Community-Acquired Pneumonia OBSOLETE 2 Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with respect to appropriate

More information

WORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation

WORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation Practical Pointers pointers For for Your your Practice practice The Multiple Facets of CAP Dr. George Fox, MD, MSc, FRCPC, FCCP Community acquired pneumonia (CAP) continues to be a significant health burden

More information

KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA

KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA Methodology: Expert opinion Issue Date: 8-97 Champion: Pulmonary Medicine Most Recent Update: 6-08, 7-10, 7-12 Key Stakeholders: Pulmonary Medicine,

More information

Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center

Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history

More information

Community Acquired Pneumonia. Abdullah Alharbi, MD, FCCP

Community Acquired Pneumonia. Abdullah Alharbi, MD, FCCP Community Acquired Pneumonia Abdullah Alharbi, MD, FCCP A 68 y/ male presented to the ED with SOB and productive coughing for 2 days. Reports poor oral intake since onset due to nausea and intermittent

More information

Making the Right Call With. Pneumonia. Community-acquired pneumonia (CAP) is a. Community-Acquired. What exactly is CAP?

Making the Right Call With. Pneumonia. Community-acquired pneumonia (CAP) is a. Community-Acquired. What exactly is CAP? Making the Right Call With Community-Acquired Pneumonia In this article: By Thomas J. Marrie, MD The case of Allyson Allyson, 32, presented to the emergency department with a 48-hour history of anorexia,

More information

Pneumonia Community-Acquired Healthcare-Associated

Pneumonia Community-Acquired Healthcare-Associated Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious

More information

Antimicrobial Stewardship in Community Acquired Pneumonia

Antimicrobial Stewardship in Community Acquired Pneumonia Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis

More information

Epidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell

Epidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell LOWER RESPIRATORY TRACT INFECTIONS Preface Thomas M. File, Jr xiii Community-Acquired Pneumonia: Pathophysiology and Host Factors with Focus on Possible New Approaches to Management of Lower Respiratory

More information

To develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.

To develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion. Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment

More information

Lecture Notes. Chapter 16: Bacterial Pneumonia

Lecture Notes. Chapter 16: Bacterial Pneumonia Lecture Notes Chapter 16: Bacterial Pneumonia Objectives Explain the epidemiology Identify the common causes Explain the pathological changes in the lung Identify clinical features Explain the treatment

More information

The Importance of Appropriate Treatment of Chronic Bronchitis

The Importance of Appropriate Treatment of Chronic Bronchitis ...CLINICIAN INTERVIEW... The Importance of Appropriate Treatment of Chronic Bronchitis An interview with Antonio Anzueto, MD, Associate Professor of Medicine, University of Texas Health Science Center,

More information

PULMONARY EMERGENCIES

PULMONARY EMERGENCIES EMERGENCIES I. Pneumonia A. Bacterial Pneumonia (most common cause of a focal infiltrate) 1. Epidemiology a. Accounts for up to 10% of hospital admissions in the U.S. b. Most pneumonias are the result

More information

Chapter 22. Pulmonary Infections

Chapter 22. Pulmonary Infections Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired

More information

PNEUMONIA IN CHILDREN. IAP UG Teaching slides

PNEUMONIA IN CHILDREN. IAP UG Teaching slides PNEUMONIA IN CHILDREN 1 INTRODUCTION 156 million new episodes / yr. worldwide 151 million episodes developing world 95% in developing countries 19% of all deaths in children

More information

Pneumococcal Pneumonia: Update on Therapy in the Era of Antibiotic Resistance

Pneumococcal Pneumonia: Update on Therapy in the Era of Antibiotic Resistance a of Antibiotic Resistance March 01, 2003 By Bernard Karnath, MD [1], Akua Agyeman, MD [2], and Albert Lai, MD [3] Sir William Osler once called pneumococcal pneumonia the captain of the men of death.

More information

Community-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.

Community-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose. Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. Community-Acquired Pneumonia Talk will focus on adults Guideline

More information

Community Acquired Pneumonia: Measures to Improve Management and Healthcare Quality

Community Acquired Pneumonia: Measures to Improve Management and Healthcare Quality Community Acquired Pneumonia: Measures to Improve Management and Healthcare Quality Gonzalo Bearman MD, MPH Assistant Professor of Internal Medicine Divisions of Quality Health Care & Infectious Diseases

More information

Pneumonia and influenza combined are the fifth leading

Pneumonia and influenza combined are the fifth leading Community-Acquired Pneumonia in Older Veterans: Does the Pneumonia Prognosis Index Help? Lona Mody, MD,* Rongjun Sun, PhD, and Suzanne Bradley, MD* OBJECTIVES: Mortality rates from pneumonia increase steadily

More information

Upper...and Lower Respiratory Tract Infections

Upper...and Lower Respiratory Tract Infections Upper...and Lower Respiratory Tract Infections Robin Jump, MD, PhD Cleveland Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University

More information

The McMaster at night Pediatric Curriculum

The McMaster at night Pediatric Curriculum The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives

More information

Respiratory Infections

Respiratory Infections Respiratory Infections NISHANT PRASAD, MD THE DR. JAMES J. RAHAL, JR. DIVISION OF INFECTIOUS DISEASES NEWYORK-PRESBYTERIAN QUEENS Disclosures Stockholder: Contrafect Corp., Bristol-Myers Squibb Co Research

More information

Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia

Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia ORIGINAL ARTICLE Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia Chiung-Zuei Chen, 1 Po-Sheng Fan, 2 Chien-Chung

More information

an inflammation of the bronchial tubes

an inflammation of the bronchial tubes BRONCHITIS DEFINITION Bronchitis is an inflammation of the bronchial tubes (or bronchi), which are the air passages that extend from the trachea into the small airways and alveoli. Triggers may be infectious

More information

Fraser Health pandemic preparedness

Fraser Health pandemic preparedness Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE

More information

Pneumonia. Definition of pneumonia Infection of the lung parenchyma Usually bacterial

Pneumonia. Definition of pneumonia Infection of the lung parenchyma Usually bacterial Pneumonia Definition of pneumonia Infection of the lung parenchyma Usually bacterial Epidemiology of pneumonia Commonest infectious cause of death in the UK and USA Incidence - 5-11 per 1000 per year Worse

More information

COPD exacerbation. Dr. med. Frank Rassouli

COPD exacerbation. Dr. med. Frank Rassouli Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»

More information

Within the past decade, the number of

Within the past decade, the number of CME EARN CATEGORY I CME CREDIT by reading this article and the article beginning on page 48 and successfully completing the posttest on page 53. Successful completion is defined as a cumulative score of

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone

More information

How do we define pneumonia?

How do we define pneumonia? Robert L. Keith MD FCCP Associate Professor of Medicine Division of Pulmonary Sciences & Critical Care Medicine Denver VA Medical Center University of Colorado Denver How do we define pneumonia? Fever

More information

Turkish Thoracic Society

Turkish Thoracic Society Türk Toraks Derneği Turkish Thoracic Society Pocket Books Series Diagnosis and Treatment of Community Acquired Pneumonia in Children Short Version (Handbook) in English www.toraks.org.tr This report was

More information

PNEUMONIA. I. Background 6 th most common cause of death in U.S. Most common cause of infection related mortality

PNEUMONIA. I. Background 6 th most common cause of death in U.S. Most common cause of infection related mortality Page 1 of 8 September 4, 2001 Donald P. Levine, M.D. University Health Center Suite 5C Office: 577-0348 dlevine@intmed.wayne.edu Assigned reading: pages 153-160; 553-563 PNEUMONIA the most widespread and

More information

Objectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children

Objectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children Objectives Community-Acquired in infants and children Review of Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America - 2011 Sabah Charania,

More information

The IDSA/ATS consensus guidelines on the management of CAP in adults

The IDSA/ATS consensus guidelines on the management of CAP in adults The IDSA/ATS consensus guidelines on the management of CAP in adults F. Piffer F. Tardini R. Cosentini U.O. Medicina d'urgenza, Gruppo NIV, Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina

More information

Pneumonia. Dr. Rami M Adil Al-Hayali Assistant professor in medicine

Pneumonia. Dr. Rami M Adil Al-Hayali Assistant professor in medicine Pneumonia Dr. Rami M Adil Al-Hayali Assistant professor in medicine Definition Pneumonia is an acute respiratory illness caused by an infection of the lung parenchyma, associated with recently developed

More information

Community acquired pneumonia

Community acquired pneumonia Community acquired pneumonia definition Symptoms of an acute LRTI New focal signs on chest examination At least one systemic feature New radiographic shadow Defination{Crofton} IT IS A SYNDROME CAUSED

More information

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation

More information

Aspiration pneumonia in older people

Aspiration pneumonia in older people Aspiration pneumonia in older people Ayman Morish, M.D. Internal medicine, Critical care Medicine and Geriatrics Fellow. Contents Epidemiology Causes of aspiration pneumonia Issues of older age Management

More information

COPD Treatable. Preventable.

COPD Treatable. Preventable. My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My

More information

A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU*

A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU* CHEST Original Research A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU* Marcos I. Restrepo, MD, MSc, FCCP; Eric M. Mortensen, MD, MSc; Jose A. Velez, MD;

More information

Community Acquired Pneumonia

Community Acquired Pneumonia April 2014 References: 1. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL Mace SE, McCracken Jr. GH, Moor MR, St. Peter SD, Stockwell JA, and Swanson JT. The Management of

More information

Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine

Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Discuss advances in predicting prognosis Understand dwhat we know (and don t know) about the Microbiology Recognize important

More information

Community Acquired & Nosocomial Pneumonias

Community Acquired & Nosocomial Pneumonias Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP

More information

11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.

11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad. The spectrum of pulmonary diseases in HIV-infected persons is broad. HIV-associated Opportunistic infections Neoplasms Miscellaneous conditions Non HIV-associated Antiretroviral therapy (ART)-associated

More information

Background. Background. Background 3/14/2014. Conflict of Interest Statement:

Background. Background. Background 3/14/2014. Conflict of Interest Statement: Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest

More information

CAP, HCAP, HAP, VAP. 1. In 1898, William Osler described community-acquired pneumonia as:

CAP, HCAP, HAP, VAP. 1. In 1898, William Osler described community-acquired pneumonia as: 1. In 1898, William Osler described community-acquired pneumonia as: Brad Sharpe, M.D. Professor of Clinical Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu I have no relevant financial

More information

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus

More information

Wright, Respiratory Infections in the Challenging Patient. Disclosures. Objectives

Wright, Respiratory Infections in the Challenging Patient. Disclosures. Objectives Respiratory Infections in the Challenging Patient Wendy L. Wright, MS, APRN, BC, FAANP, FAAN Adult / Family Nurse Practitioner Owner - Wright & Associates Family Healthcare Amherst, New Hampshire Owner

More information

MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION

MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA IN THE ASIA PACIFIC REGION Chong-Kin LIAM Department of Medicine Faculty of Medicine University of Malaya Kuala Lumpur liamck@ummc.edu.my COMMUNITY ACQUIRED PNEUMONIA

More information

Treatment of febrile neutropenia in patients with neoplasia

Treatment of febrile neutropenia in patients with neoplasia Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece

More information

Disclosures. Case 1. Acute Bronchitis. Acute Bronchitis. Community-Acquired Pneumonia and other Respiratory Tract Infections. What do you recommend?

Disclosures. Case 1. Acute Bronchitis. Acute Bronchitis. Community-Acquired Pneumonia and other Respiratory Tract Infections. What do you recommend? Community-Acquired Pneumonia and other Respiratory Tract Infections none Disclosures Joel T. Katz, M.D. Associate Professor of Medicine Division of Infectious Diseases Brigham and Women s Hospital Case

More information

Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT

Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience

More information

Nosocomial Pneumonia. <5 Days: Non-Multidrug-Resistant Bacteria

Nosocomial Pneumonia. <5 Days: Non-Multidrug-Resistant Bacteria Nosocomial Pneumonia Meredith Deutscher, MD Troy Schaffernocker, MD Ohio State University Burden of Hospital-Acquired Pneumonia Second most common nosocomial infection in the U.S. 5-10 episodes per 1000

More information

Patient information: Pneumonia in adults (Beyond the Basics)

Patient information: Pneumonia in adults (Beyond the Basics) Page 1 of 8 Official reprint from UpToDate www.uptodate.com 2014 UpToDate Patient information: Pneumonia in adults (Beyond the Basics) Authors Thomas J Marrie, MD Thomas M File, Jr, MD Section Editor John

More information

CARE OF THE ADULT PNEUMONIA PATIENT

CARE OF THE ADULT PNEUMONIA PATIENT Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated

More information

Critical Care Nursing Theory. Pneumonia. - Pneumonia is an acute infection of the pulmonary parenchyma

Critical Care Nursing Theory. Pneumonia. - Pneumonia is an acute infection of the pulmonary parenchyma - is an acute infection of the pulmonary parenchyma - is a common infection encountered by critical care nurses when it complicates the course of a serious illness or leads to acute respiratory distress.

More information

Setting The setting was secondary care. The economic study was carried out in the USA.

Setting The setting was secondary care. The economic study was carried out in the USA. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Paladino J A, Gudgel L D, Forrest A, Niederman

More information

High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia

High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Review Andrew F. Shorr, MD, MPH, FCCP Department of Medicine Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington,

More information

Preventing and Treating Community-Acquired Pneumonia

Preventing and Treating Community-Acquired Pneumonia PL Detail-Document #310618 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2015 Preventing and Treating

More information

Chest radiography in patients suspected of pneumonia in primary care: diagnostic yield, and consequences for patient management

Chest radiography in patients suspected of pneumonia in primary care: diagnostic yield, and consequences for patient management Chest radiography in patients suspected of pneumonia in primary care: diagnostic yield, and consequences for patient management 4 Speets AM, Hoes AW, Van der Graaf Y, Kalmijn S, Sachs APE, Mali WPThM.

More information

Management of Acute Exacerbations

Management of Acute Exacerbations 15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society

More information

Unit II Problem 2 Pathology: Pneumonia

Unit II Problem 2 Pathology: Pneumonia Unit II Problem 2 Pathology: Pneumonia - Definition: pneumonia is the infection of lung parenchyma which occurs especially when normal defenses are impaired such as: Cough reflex. Damage of cilia in respiratory

More information

Hospital-acquired Pneumonia

Hospital-acquired Pneumonia Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired

More information

UPDATE IN HOSPITAL MEDICINE

UPDATE IN HOSPITAL MEDICINE UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some

More information

Choosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens

Choosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents

More information

Pneumonia: The Forgotten Killer

Pneumonia: The Forgotten Killer Pneumonia: The Forgotten Killer David Glenn Weismiller, MD, ScM, FAAFP Department of Family and Community Medicine University of Nevada, Las Vegas School of Medicine Disclosure Statement It is the policy

More information

Acute Respiratory Infection. Dr Anthony Gibson

Acute Respiratory Infection. Dr Anthony Gibson Acute Respiratory Infection Dr Anthony Gibson Range of Conditions Upper tract Common Cold coryza Sore Throat- Pharyngitis Sinusitis Epiglottitis Range of Conditions Lower Acute Bronchitis Acute Exacerbation

More information

The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease ...SYMPOSIUM PROCEEDINGS... The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Robert E. Hillberg, MD Presentation Summary Chronic obstructive pulmonary disease (COPD)

More information

Community Acquired Pneumonia-Adults Clinical Practice Guideline MedStar Health

Community Acquired Pneumonia-Adults Clinical Practice Guideline MedStar Health Community Acquired Pneumonia-Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care of their patients.

More information

Prospective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital

Prospective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital Prospective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital Final Results Nathan Beahm, BSP, PharmD(student) September 10, 2016 Objectives Review background information

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

Pneumonia Severity Scores:

Pneumonia Severity Scores: Pneumonia Severity Scores: Are they Accurate Predictors of Mortality? JILL McEWEN, MD FRCPC Clinical Professor Department of Emergency Medicine University of British Columbia Vancouver, BC Canada President,

More information

Bronchitis/Pneumonia Core Content Keith Conover, M.D., FACEP /15/02 Clinical Spectrum Chest pain, shoulder pain, neck pain, abdominal pain,

Bronchitis/Pneumonia Core Content Keith Conover, M.D., FACEP /15/02 Clinical Spectrum Chest pain, shoulder pain, neck pain, abdominal pain, Bronchitis/Pneumonia Core Content Keith Conover, M.D., FACEP 1.0 10/15/02 Clinical Spectrum Chest pain, shoulder pain, neck pain, abdominal pain, headache Links with smoking, pollen count, FH of asthma

More information

PNEUMONIA. Patient Case: Chief Complaint: I have been short of breath and have been coughing up rust-colored phlegm for the past 3 days.

PNEUMONIA. Patient Case: Chief Complaint: I have been short of breath and have been coughing up rust-colored phlegm for the past 3 days. PNEUMONIA Relevant Guidelines: 2008 IDSA CAP guidelines: http://www.idsociety.org/guidelines/patient_care/idsa_practice_guidelines/infections_by_org an_system/lower/upper_respiratory/community-acquired_pneumonia_(cap)/

More information

Community Acquired Pneumonia in Adults Clinical Practice Guideline Antibiotic Stewardship

Community Acquired Pneumonia in Adults Clinical Practice Guideline Antibiotic Stewardship Community Acquired Pneumonia in Adults Clinical Practice Guideline Antibiotic Stewardship These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care

More information

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing National Institute for Health and Care Excellence Final Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing Evidence review December 2018 Contents Disclaimer The recommendations

More information

Community Acquired Pneumonia - Pediatric Clinical Practice Guideline MedStar Health Antibiotic Stewardship

Community Acquired Pneumonia - Pediatric Clinical Practice Guideline MedStar Health Antibiotic Stewardship Community Acquired Pneumonia - Pediatric Clinical Practice Guideline MedStar Health Antibiotic Stewardship These guidelines are provided to assist physicians and other clinicians in making decisions regarding

More information

Getting Smart About: Upper Respiratory Infections

Getting Smart About: Upper Respiratory Infections Getting Smart About: Upper Respiratory Infections Daniel Z. Uslan, MD Assistant Clinical Professor Director, Antimicrobial Stewardship Program UCLA Health System Disclosures None relevant to the topic

More information

Mædica - a Journal of Clinical Medicine

Mædica - a Journal of Clinical Medicine Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Mortality Risk and Etiologic Spectrum of Community-acquired Pneumonia in Hospitalized Adult Patients Cornelia TUDOSE, Assistant Professor of Pneumology;

More information

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.

More information

Community Acquired Pneumonia Pediatric Ages 3 month to 18 years Clinical Practice Guideline MedStar Health Antibiotic Stewardship

Community Acquired Pneumonia Pediatric Ages 3 month to 18 years Clinical Practice Guideline MedStar Health Antibiotic Stewardship Community Acquired Pneumonia Pediatric Ages 3 month to 18 years Clinical Practice Guideline MedStar Health Antibiotic Stewardship These guidelines are provided to assist physicians and other clinicians

More information

Outpatient Management of Patients With Community Acquired Pneumonia Clinical Practice Guideline September 2013

Outpatient Management of Patients With Community Acquired Pneumonia Clinical Practice Guideline September 2013 Clinical Practice Guideline September 2013 General Principles: Community Acquired Pneumonia (CAP), together with influenza, remains the seventh leading cause of death in the United States. According to

More information

Integrated Cardiopulmonary Pharmacology Third Edition

Integrated Cardiopulmonary Pharmacology Third Edition Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive

More information

Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults 000 GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults John G. Bartlett, 1 Scott F. Dowell, 2 Lionel A. Mandell,

More information

Respiratory tract infections. Krzysztof Buczkowski

Respiratory tract infections. Krzysztof Buczkowski Respiratory tract infections Krzysztof Buczkowski Etiology Viruses Rhinoviruses Adenoviruses Coronaviruses Influenza and Parainfluenza Viruses Respiratory Syncitial Viruses Enteroviruses Etiology Bacteria

More information

Diffusion: Oxygen in the alveoli move into capillaries to go to the body, and carbon

Diffusion: Oxygen in the alveoli move into capillaries to go to the body, and carbon 1 2 Oxygenation and Perfusion Alina Ruiz, MSN-Ed., RN Anatomy and Physiology of Oxygenation What does the respiratory system do? 3 4 5 6 7 Lungs: Ventilation vs Respiration vs Perfusion Ventilation is

More information

(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055

(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055 IJPSR (2014), Vol. 5, Issue 5 (Research Article) Received on 29 November, 2013; received in revised form, 21 February, 2014; accepted, 16 April, 2014; published 01 May, 2014 EVALUATION OF EFFICACY AND

More information

Pneumonia in the Hospitalized

Pneumonia in the Hospitalized Pneumonia in the Hospitalized Patient: Use of Steroids Nicolette Myers, MD Pulmonary/Sleep/Critical Care November 9, 2018 Park Nicollet Clinic Facts About Pneumonia CAP is the 8 th most common cause of

More information

Pathology of Pneumonia

Pathology of Pneumonia Pathology of Pneumonia Dr. Atif Ali Bashir Assistant Professor of Pathology College of Medicine Majma ah University Introduction: 5000 sq meters of area.! (olympic track) Filters >10,000 L of air / day!

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory

More information

Bradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF -- William Osler, M.D.

Bradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF -- William Osler, M.D. Bradley A. Sharpe, M.D. Associate Professor Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu a. An ailment that often leads to suffocation and death. b. A friend of the aged. c. A common

More information

Upper Respiratory Tract Infections

Upper Respiratory Tract Infections Upper Respiratory Tract Infections OTITIS MEDIA Otitis media is an inflammation of the middle ear. There are more than 709 million cases of otitis media worldwide each year; half of these cases occur in

More information

Guideline for the Diagnosis and Management of COPD

Guideline for the Diagnosis and Management of COPD Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially

More information

High dose amoxicillin for sinusitis

High dose amoxicillin for sinusitis High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018

More information

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. 1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness

More information

JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections

JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

Septic Shock. Rontgene M. Solante, MD, FPCP,FPSMID

Septic Shock. Rontgene M. Solante, MD, FPCP,FPSMID Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage

More information

Guidelines/Guidance/CAP/ Hospitalized Child. PHM Boot Camp 2014 Jay Tureen, MD June 19, 2014

Guidelines/Guidance/CAP/ Hospitalized Child. PHM Boot Camp 2014 Jay Tureen, MD June 19, 2014 Guidelines/Guidance/CAP/ Hospitalized Child PHM Boot Camp 2014 Jay Tureen, MD June 19, 2014 CAP in Children: Epi Greatest cause of death in children worldwide Estimated > 2 M deaths in children In developed

More information